Answers are grounded in this paper and cite their sources.
Long-term low-dose MTX is safe in RA patients in the Indian population. The patterns of adverse effects were similar to those documented in earlier studies. However, our study results suggest that disease duration, cumulative MTX dose, concomitant DMARD intake are not risk factors associated with hepatic or hematological adverse effects.
No takes yet. Share an insight, caveat, or question.
Dubey et al. (2016) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: